Literature DB >> 6559049

Partial deficiency of the fourth component of human complement (C4) and autoantibody directed against C4 in a patient with SLE.

J Ripoche, M Fontaine, M Godin, G Hauptmann, J Goetz.   

Abstract

The finding of dramatically depressed levels of C4 in a 17-year old patient with severe systemic lupus erythematosus (SLE) prompted a genetic study of her family. This study revealed the existence of a partial C4 deficiency; we found the presence of a C4A3,C4BQo haplotype which was transmitted by the mother to each of her children. This patient possessed, in her serum, an autoantibody with anti-C4 specificity. The immunochemical characterization of this autoantibody revealed that it was IgM and belonged to the immunoconglutinin family. We have studied the effects of this autoantibody on the formation and dissociation kinetics of classical C3-convertase.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6559049     DOI: 10.1016/s0771-050x(83)80089-8

Source DB:  PubMed          Journal:  Ann Immunol (Paris)        ISSN: 0300-4910


  3 in total

1.  Family study of the major histocompatibility complex in HLA DR3 negative patients with systemic lupus erythematosus.

Authors:  J R Batchelor; A H Fielder; M J Walport; J David; D K Lord; N Davey; I A Dodi; P Malasit; W Wanachiwanawin; R Bernstein
Journal:  Clin Exp Immunol       Date:  1987-11       Impact factor: 4.330

Review 2.  The Immunopathology of Complement Proteins and Innate Immunity in Autoimmune Disease.

Authors:  Federica Defendi; Nicole M Thielens; Giovanna Clavarino; Jean-Yves Cesbron; Chantal Dumestre-Pérard
Journal:  Clin Rev Allergy Immunol       Date:  2020-04       Impact factor: 8.667

3.  Loading of nuclear autoantigens prototypically recognized by systemic lupus erythematosus sera into late apoptotic vesicles requires intact microtubules and myosin light chain kinase activity.

Authors:  M Zirngibl; B G Fürnrohr; C Janko; L E Munoz; R E Voll; C D Gregory; G Schett; M Herrmann
Journal:  Clin Exp Immunol       Date:  2015-01       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.